![logo](/logos/CVM.webp)
CEL-SCI Corporation
AMEX:CVM
2.6 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | CEL-SCI Corporation |
Symbool | CVM |
Munteenheid | USD |
Prijs | 2.18 |
Beurswaarde | 103,027,018 |
Dividendpercentage | 0% |
52-weken bereik | 1.04 - 3.33 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Geert R. Kersten Esq. |
Website | https://cel-sci.com |
An error occurred while fetching data.
Over CEL-SCI Corporation
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)